Bevacizumab in metastatic colorectal cancer: a left intracardiac thrombotic event.
Roncalli
J
J
Delord
J P
JP
Galinier
M
M
Massabuau
P
P
Lescure
M
M
Fauvel
J M
JM
Azria
D
D
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D003328:Coronary Thrombosis / Q000139:chemically induced / Q000175:diagnosis*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D018487:Ventricular Dysfunction, Left / Q000209:etiology*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068258:Bevacizumab; D005472:Fluorouracil